Sign inJoin waitlistJoin the waitlist

Angeles Secord

Associate Professor of Obstetrics and Gynecology · Duke University Hospital

Credentials: · · · ·

History

Duke University Hospital
Present
Duke University Hospital
Present
University of Colorado School of Medicine
Present

Duke University Hospital
1998–2001
Obstetrics and Gynecology
Duke University Hospital
1994–1998
University of Washington School of Medicine
1990–1994

Research

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology · 2019 · 431 citations
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor…
Journal of Clinical Oncology · 2018 · 400 citations
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Journal of Clinical Oncology · 2007 · Last of 11 authors · 335 citations

Laura Havrilesky
87 papers · 2 as a fellow
Andrew Berchuck
45 papers · 6 as a resident
Paola Gehrig
26 papers
PL
Paula Lee
25 papers · 6 as a fellow
Rebecca Previs
20 papers · 7 as a fellow
Brittany Davidson
19 papers · 4 as a fellow
Kathleen Moore
18 papers · 4 as a resident
Victoria Bae-Jump
18 papers · 1 as a fellow
Matthew Powell
16 papers
David O'Malley
15 papers
David Mutch
13 papers
Bradley Monk
12 papers

Grants

The Duke University - Duke Cancer Institute National Clinical Trials Network LAPS (UG1) Support Grant
National Cancer Institute · UG1
PI · $3.1M · Duke University
2019–2026
Angiogenic Biomarker Discovery to Direct Bevacizumab Therapy in Cervical Cancer - Blood-Based Angiome Profiling: An Ancillary Analysis of GOG-0240
National Cancer Institute · R21
Contact PI · $391.2K · Duke University
2021–2023
NCI National Clinical Trials Network U10
National Cancer Institute · U10
PI · $2M · Duke University
2014–2019
Blood-Based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer
National Cancer Institute · R21
Contact PI · $377.8K · Duke University
2014–2017

Clinical trials

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
Principal investigator · Not yet recruiting · Phase 1, Phase 2
BioMimetix JV, LLC
2025–2027
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
Principal investigator · Completed · Phase 1, Phase 2
Duke University
2018–2020
Endometrial Cancer Diet and Exercise
Principal investigator · Completed
Duke University
2017–2019
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Principal investigator · Completed · Early phase 1
AA Secord
2016–2022